Abstract:Dear Editor, It was proposed by Haider and Ashraf1 that cytokine and growth factor mediated mobilization of endogenous mesenchymal stem cells from their bone marrow niches for homing into the infarcted myocardium could be a better therapeutic strategy than the explantation and subsequent injection of these cells (either autologous or from a donated allogenic source) directly into the damaged heart.2 Besides being less invasive to the patient, it was argued that this approach would obviate the need for ex vivo processing of the putative stem cells, which could in turn reduce the risk of nonspecific differentiation into undesired lineages at the transplantation site.3–5 Nevertheless, such an approach could be severely hampered by the age related decline in the regenerative capacity of the putative mesenchymal stem cell population within the bone marrow, as has been demonstrated by a number of studies.6,7 It must be remembered that the overwhelming majority of myocardial infarct cases occur in the older segment of the population.8 Quarto and colleagues6 demonstrated in a rat model that there was an age associated decline in the ability of marrow stromal cells to repair bone, which could be the underlying cause of age related osteodegenerative diseases. Subsequently, D’Ippolito and colleagues7 reported a similar finding with the human model. This would be expected because, with increasing age, the putative mesenchymal stem cell population within the bone marrow would have gone through more rounds of cell division, in addition to having been exposed to free radicals and metabolic toxins over a longer lifespan. Hence it is no surprise that there is a gradual decline in their regenerative capacity with increasing age. Although there have been no studies to date that have conclusively demonstrated an age associated decline in the capacity of bone marrow cells to repair the infarcted heart, we could make such a conjecture based upon extrapolation from the bone repair model.6,7 The obvious solution to overcome this age related decline in regenerative capacity would be to look at donated allogenic sources of stem cells for myocardial repair. In this regard, human embryonic stem (hES) cells or their differentiated progenies would hold much promise because these potentially represent an abundant and readily available source of transplantable cells. Recently, Zandstra and colleagues9 successfully developed a scalable, robust, and reproducible process for obtaining purified cardiomyocytes from hES cells. Nevertheless, the immunologic barrier10 probably represents the most formidable challenge to the allogenic transplantation of hES cells or their differentiated progenies into the infarcted myocardium. It is hoped that this could somehow be overcome in the near future. Boon Chin Heng* Eugene Kwang-Wei Sim† Tong Cao* *Stem Cell Laboratory, Faculty of Dentistry, †Department of Surgery, Faculty of Medicine National University of Singapore.

Can we remove scar and fibrosis from adult human myocardium?

Reply to Letter from Drs. Haider and Ashraf

Comments about Possible Use of Human Embryonic Stem Cell-Derived Cardiomyocytes to Direct Autologous Adult Stem Cells into the Cardiomyogenic Lineage

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

View from the heart: cardiac fibroblasts in development, scarring and regeneration

Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities

Direct Reprogramming of Cardiac Fibroblasts to Repair the Injured Heart

Regeneration of the myocardium: a new role in the treatment of ischemic heart disease?

The adaptive immune response to cardiac injury—the true roadblock to effective regenerative therapies?

Acellular bioscaffolds redirect cardiac fibroblasts and promote functional tissue repair in rodents and humans with myocardial injury

Stem cell therapy for cardiac repair: benefits and barriers

Possible Muscle Repair in the Human Cardiovascular System

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

Harnessing stem cell and lineage reprogramming technology to treat cardiac fibrosis

Cardiac Cell Therapy for Heart Repair: Should the Cells Be Left Out?

Myocardial regeneration: present and future trends

Leading Progress in Heart Regeneration and Repair

Stem Cell Antigen-1+Cell-derived Fibroblasts Are Crucial for Cardiac Fibrosis During Heart Failure.

[Treatment of cardiac fibrosis: from neurohormonal antagonists to CAR-T cells]

Scarring and Skin Fibrosis Reversal with Regenerative Surgery and Stem Cell Therapy

Characterization of cardiac fibroblast-extracellular matrix crosstalk across developmental ages provides insight into age-related changes in cardiac repair